Septerna, Inc. (NASDAQ: SEPN)

Septerna, Inc. is a clinical-stage biotechnology company that pioneers oral small molecule drug discovery targeting G protein coupled receptors using its proprietary Native Complex Platform. The company focuses initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its platform enables the isolation and structural determination of G protein coupled receptors in a native lipid environment to design agonists antagonists and allosteric modulators.

Septerna generates revenue primarily through collaboration agreements with pharmaceutical partners. The company has entered into a global collaboration with Novo Nordisk that includes an upfront payment of one hundred ninety five million dollars potential milestone payments of up to four hundred ninety eight million dollars per program and tiered royalties ranging from mid to high single digits on global product sales. As a clinical-stage entity Septerna does not yet have product sales revenue.

Septerna positions itself as an innovator in the field of G protein coupled receptor drug discovery by offering a platform that can isolate native receptor complexes outside the cell. This capability addresses a major limitation that has hindered the development of oral small molecules for many G protein coupled targets. While large pharmaceutical companies and other biotech firms also pursue G protein coupled therapies Septerna’s proprietary technology and deep pipeline in endocrinology immunology inflammation and metabolic diseases provide a differentiated approach. Competitors include established pharma companies with existing GPCR drugs and other platform based biotechs but Septerna aims to leverage its structural biology focus to expand the druggable repertoire of G protein coupled receptors.

Septerna serves patients with significant unmet medical needs in the areas of hypoparathyroidism chronic spontaneous urticaria Graves disease and thyroid eye disease as well as broader metabolic disorder populations. The company collaborates with Novo Nordisk to advance therapeutics for metabolic targets such as GLP1 GIP and glucagon receptors. No other specific customer names are disclosed in the filing.